Disease
Non-Small Cell Lung Cancer
The most common form of lung cancer (~77% of cases), spanning adenocarcinoma, squamous cell carcinoma, and large cell carcinoma histologies. Treatment is heavily biomarker-driven -- EGFR, ALK, KRAS G12C, MET exon 14, ROS1, RET, HER2, and PD-L1 status each define a distinct targeted-therapy or immunotherapy pathway.
Total attributable cost
$12.5B
$70,896/patient
Drug spend
$4.8B
$27,138/patient
38% of total cost is drugs
All stages, newly diagnosed (2026 incidence estimate) · US